Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC3: PegIntron Maintenance in HCV Cirrhosis
NCT00048724Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Apr 2008
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in hepatitis C virus infection (2 arms), sponsored by Merck & Co. Primary endpoint: Time to Observation of the First Clinical Event Experienced by a Subject at 60 months. Started Jun 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00048724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048724.